Subcutaneous Immunoglobulin Replacement Therapy with Hizentra® is Safe and Effective in Children Less Than 5 Years of Age

Journal of Clinical Immunology
Niraj C PatelElie Haddad

Abstract

Hizentra® (IGSC 20%) is a 20% liquid IgG product approved for subcutaneous administration in adults and children 2 years of age and older who have primary immunodeficiency disease (PIDD). There is limited information about the use of IGSC 20 % in very young children including those less than 5 years of age. A retrospective chart review involved 88 PIDD infants and children less than 5 years of age who received Hizentra®. The mean age at the start of Hizentra® was 34 months (range 2 to 59 months). IGSC 20 % was administered weekly to 86 infants (two additional infants received twice weekly and three times weekly infusions, respectively) and included an average of 63 infusions (range 6-182) for an observation period up to 45.5 months. Infusion by manual delivery occurred in 15 patients. The mean dose was 674 mg/kg/4 weeks. The mean IgG level was 942 mg/dL while on IGSC 20 %, compared to a mean trough IgG level of 794 mg/dL (p < 0.0001) during intravenous or subcutaneous IgG administration prior to IGSC 20 %. Average infusion time was 47 (range 5-120) minutes, and the median number of infusion sites was 2 (range 1-4). Local reactions were mostly mild and observed in 36/88 (41%) children. No serious adverse events were reported. A ...Continue Reading

References

Nov 1, 1969·The British Journal of Nutrition·A Ashworth
Dec 4, 1993·Lancet·M J ThomasH H Chapel
Mar 1, 1993·The American Journal of Clinical Nutrition·I KabirD Mahalanabis
Jul 22, 1999·Clinical Immunology : the Official Journal of the Clinical Immunology Society·C Cunningham-Rundles, C Bodian
Nov 4, 2000·The New England Journal of Medicine·R H Buckley
Jun 14, 2002·The Journal of Allergy and Clinical Immunology·Paula Jane BusseCharlotte Cunningham-Rundles
Mar 26, 2003·Clinical and Experimental Immunology·H ChapelUNKNOWN IUIS PID (Primary Immunodeficiencies) Classification committee
Jun 20, 2006·Journal of Clinical Immunology·Hans D OchsUNKNOWN Subcutaneous IgG Study Group
Apr 22, 2008·Immunology and Allergy Clinics of North America·Melvin Berger
May 11, 2011·Clinical Pharmacokinetics·Richard L WassermanJoseph A Church
Jun 28, 2011·Clinical Immunology : the Official Journal of the Clinical Immunology Society·S JollesB Grimbacher
Jan 10, 2012·Journal of Clinical Immunology·Joel L Gallagher, Niraj C Patel
Apr 21, 2012·Advances in Nutrition·Stephanie A RichardWilliam Checkley
Jan 22, 2013·Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology·Ralph S Shapiro
Mar 5, 2013·Journal of Clinical Immunology·Melvin BergerJohn W Sleasman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.